Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBC088 for Refractory Childhood-onset SLE
NCT06934447Phase 1Recruiting
- Sponsor
- Children's Hospital, Zhejiang University School of Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-BCMA/CD70-CAR-T cells in systemic lupus erythematosus (SLE), sponsored by Children's Hospital, Zhejiang University School of Medicine. Primary endpoints: Safety of BCMA/CD70 CAR-T cell therapy at 3 months and Efficiency of CAR-T cell therapy at 6 months. Started Apr 2025; status: recruiting.
02
Drugs
anti-BCMA/CD70-CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06934447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934447.